This trial is active, not recruiting.

Conditions hiv, emphysema, hiv infections
Sponsor Philip Diaz
Collaborator National Institutes of Health (NIH)
Start date March 2006
End date December 2015
Trial size 365 participants
Trial identifier NCT00823927, 2005H0197


This study is being done to examine lung function changes in individuals with HIV infection and to understand why individuals with HIV have increased risk of lung damage from cigarette smoking.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
HIV smokers with emphysema
HIV smokers without emphysema

Primary Outcomes

examine the natural history of smoking related lung damage in patients with HIV
time frame: 3 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Clinically stable HIV-seropositive (and HIV-seronegative) individuals - Ages 18 years and older - Female subjects on no oral contraception with a negative pregnancy test - Subjects capable of giving written consent Exclusion Criteria: - Known medical illness that would preclude bronchoscopy/BAL (e.g. unstable angina, new cardiac arrhythmia). This only pertains to subjects involved in the bronchoscopy phase of the study. - Pregnant females - Prisoners

Additional Information

Official title Alveolar Macrophage Proteomics in HIV-associated Emphysema
Principal investigator Philip T Diaz, MD
Description To delineate the natural history of HIV associated emphysema in the HAART era. To compare the alveolar macrophage proteomes from HIV-seropositive smokers with emphysema to the alveolar macrophages proteomes of both HIV+ smokers without emphysema and HIV- smokers. To establish whether coinfection with HIV and Hepatitis C results in accelerated lung disease manifested by decrements in forced expiratory volume and carbon monoxide diffusing capacity.
Trial information was received from ClinicalTrials.gov and was last updated in April 2015.
Information provided to ClinicalTrials.gov by Ohio State University.